JP2007538024A5 - - Google Patents

Download PDF

Info

Publication number
JP2007538024A5
JP2007538024A5 JP2007517041A JP2007517041A JP2007538024A5 JP 2007538024 A5 JP2007538024 A5 JP 2007538024A5 JP 2007517041 A JP2007517041 A JP 2007517041A JP 2007517041 A JP2007517041 A JP 2007517041A JP 2007538024 A5 JP2007538024 A5 JP 2007538024A5
Authority
JP
Japan
Prior art keywords
group
alkyl
phenyl
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007517041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007538024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/005229 external-priority patent/WO2005110422A2/en
Publication of JP2007538024A publication Critical patent/JP2007538024A/ja
Publication of JP2007538024A5 publication Critical patent/JP2007538024A5/ja
Pending legal-status Critical Current

Links

JP2007517041A 2004-05-19 2005-05-13 アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物 Pending JP2007538024A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011894 2004-05-19
PCT/EP2005/005229 WO2005110422A2 (en) 2004-05-19 2005-05-13 Treatment of diseases associated with altered level of amyloid beta peptides

Publications (2)

Publication Number Publication Date
JP2007538024A JP2007538024A (ja) 2007-12-27
JP2007538024A5 true JP2007538024A5 (https=) 2008-07-03

Family

ID=34979633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007517041A Pending JP2007538024A (ja) 2004-05-19 2005-05-13 アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物

Country Status (5)

Country Link
US (4) US7393843B2 (https=)
EP (1) EP1750719A2 (https=)
JP (1) JP2007538024A (https=)
CA (1) CA2567223A1 (https=)
WO (1) WO2005110422A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534541A (ja) * 2005-03-30 2008-08-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換1,2−エチレンジアミン、前記化合物を含む薬物、それらの使用及びそれらの製造方法
EP1913017A1 (en) * 2005-08-03 2008-04-23 Boehringer Ingelheim International GmbH Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
US20100168070A1 (en) * 2005-08-11 2010-07-01 Niklas Heine Compounds for the treatment of alzheimer's disease
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
US20110105602A2 (en) * 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
CA2689930A1 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
CA2689948A1 (en) 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
CA2695543A1 (en) * 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
MX2010005028A (es) 2007-11-05 2010-05-27 Schering Corp Moduladores de gamma secretasa.
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010075204A2 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
US20100233156A1 (en) * 2009-03-09 2010-09-16 Georgetown University Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
CN102438622A (zh) * 2009-03-19 2012-05-02 百时美施贵宝公司 作为β淀粉样肽产生抑制剂的新颖α-(N-磺酰氨基)乙酰胺化合物
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US10160789B2 (en) 2011-03-14 2018-12-25 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP3313866B1 (en) 2015-06-29 2024-11-20 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant
CN118791377B (zh) * 2024-09-10 2025-02-07 山东国邦药业有限公司 一种2,4,5-三氟苯乙酸的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674876A (en) 1969-06-09 1972-07-04 Pfizer Benzothiazine dioxides as lipid regulating agents
US3998954A (en) * 1971-02-05 1976-12-21 Pfizer Inc. 1,3(2H,4H)-Dioxoisoquinoline-4-carboxamides used as anti-inflammatory agents
US3891637A (en) 1974-10-01 1975-06-24 Pfizer Process for the production of carboxamides of oxo-1,2-benzothiazine-1,1-dioxides
MC1135A1 (fr) 1976-02-23 1977-11-18 Hoffmann La Roche Derives de thiazine
US4175085A (en) 1976-02-23 1979-11-20 Hoffmann-La Roche Inc. Thienothiazine derivatives
LU78009A1 (de) 1977-08-22 1979-05-23 Hoffmann La Roche Verfahren zur herstellung von thiazinderivaten
US4683306A (en) 1984-07-13 1987-07-28 Yuhan Corporation Co., Ltd. Process for the preparation of 3,4-dihydro-2-substituted-2H-1,2-thiazine-carboxylic acid 1,1-dioxide derivatives
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
ES2236682T5 (es) * 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
JPH05286941A (ja) * 1991-09-30 1993-11-02 Nippon Zeon Co Ltd ピリジン−2,6−ジオン誘導体
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) * 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
KR20020013961A (ko) 1999-07-16 2002-02-21 룬딩 에른스트 신규한 아미노벤조페논
EP1212101A1 (en) * 1999-08-31 2002-06-12 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
JP2003530437A (ja) 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Aβ42低下物質
WO2003040691A2 (en) * 2001-11-05 2003-05-15 The Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases

Similar Documents

Publication Publication Date Title
JP2007538024A5 (https=)
JP2010523476A5 (https=)
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2006524660A5 (https=)
JP2011509309A5 (https=)
JP2013508279A5 (https=)
JP2007519649A5 (https=)
JP2014511891A5 (https=)
JP2005539088A5 (https=)
JP2014530900A5 (https=)
JP2011516511A5 (https=)
JP2016040288A5 (https=)
JP2010523522A5 (https=)
JP2008539267A5 (https=)
JP2012533546A5 (https=)
JP2008539268A5 (https=)
JP2013531070A5 (https=)
JP2007508360A5 (https=)
JP2017517538A5 (https=)
JP2012532883A5 (https=)
JP2007507494A5 (https=)
JP2010155827A5 (https=)
JP2019520344A5 (https=)
JP2008512408A5 (https=)
JP2013513607A5 (https=)